Latest Leadership News

Echo IQ has completed a pivotal clinical validation of its EchoSolv HF software at the Mayo Clinic, achieving outstanding accuracy ahead of its FDA submission. This milestone sets the stage for potential US market entry into a $60 billion heart failure diagnostics sector.

Black Cat Syndicate announces a leadership transition with James Bruce appointed as Managing Director from April 2026, succeeding founder Gareth Solly who will remain as a Non-Executive Director.

Gentrack Group reported robust FY25 results with an 8% revenue rise to NZ$230.2m and a 119% jump in net profit, driven by strong growth in utilities and airports segments alongside strategic investments in its new cloud platform and global expansion.

Gentrack Group reported a strong FY25 with revenue up 8% and net profit more than doubling, driven by key deployments of its new g2.0 cloud platform and robust growth in its airports division Veovo.

Verbrec Limited reported record FY2025 financial results with its highest gross and adjusted EBITDA margins in years, alongside strategic moves including the acquisition of Alliance Automation and divestment of its Competency Training business.

Verbrec Limited has reported a strong FY2025 with record margins and resumed dividend payments after more than a decade, alongside strategic moves including a key acquisition and divestment.

Adore Beauty Group has reported record profitability for FY25, driven by improved revenue quality, operational efficiencies, and rapid retail expansion. The company’s omni-channel strategy is gaining momentum with strong customer growth and a new fulfillment center planned for FY27.

Elevra Lithium reports a 31% surge in spodumene concentrate production for FY25, alongside significant resource expansions and a clear growth roadmap post-merger.

Infragreen Group Limited has reported a strong FY25 performance, exceeding prospectus forecasts with $18.6 million in pro forma EBITDA and a successful $40 million IPO. The company projects robust growth in FY26, driven by organic expansion and strategic acquisitions in sustainable infrastructure.

Reece Limited reported a modest revenue decline and earnings pressure in FY25 amid challenging markets but reinforced its long-term growth strategy with a significant share buyback and board renewal. Early FY26 trading shows sales growth driven by network expansion despite ongoing cost pressures.

Lynch Group Holdings Limited shareholders convened to vote on a proposed $2.155 per share acquisition by Hasfarm Bidco, with strong board and expert backing. The scheme offers a significant premium and awaits final court approval.

Alterity Therapeutics announces significant board changes, including the retirement of founding chairman Geoffrey Kempler and appointment of CEO Dr David Stamler as Managing Director, aligning leadership with its Phase 3 clinical ambitions.